In a feature article about migrant detainees, Dawn Nolt, M.D., M.P.H., comments on the impact of influenza: “Flu is uncommon at this time of year. That someone died of the flu is certainly something to be very worried about.”

News coverage explores extreme reclusive behavior endemic in Japan, following knife attacks. Alan Teo, M.D., says, “The scope of the problem is in terms of hundreds of thousands of individuals who have been in this protracted state of withdrawal without active engagement in mental health care.”

Shoukhrat Mitalipov, Ph.D., is quoted regarding a new discovery about the gene-editing tool CRISPR.

Shoukhrat Mitalipov, Ph.D., argues that the U.S. Food and Drug Administration should be allowed to oversee clinical trials in techniques to prevent inherited disease.

Joe Gray, Ph.D., testified before the U.S. Senate Committee on Finance on the importance of importance of international collaboration in scientific research.

Ajit Jetmalani, M.D., participates in a live KATU-TV Town Hall focused on the importance of adolescents identifying, understanding and facing mental health challenges.

Peter Barr-Gillespie, Ph.D., will be one of two prominent hearing loss researchers speaking at a New York Academy of Sciences symposium in October. EIN Presswire news release picked up in outlets across the country.

Technology Networks spotlights Brian Druker, M.D.’s, work to develop the drug Gleevec as one of the “10 Modern Milestones in Cancer Research.”

In the face of the national opioid epidemic, some surgeons are focused on offering non-opioid alternatives to help patients manage pain after surgery. Maisie Shindo, M.D., says, “It really depends on the expectations that are set with the patient ahead of time about how the pain is going to be managed. This also includes explaining to patients that they are going to have some discomfort.”

Christopher Terndrup, M.D., comments on a recent study about how widely used Pre Exposure Prophylasix, or PrEP, is among HIV-negative males. He says: “It's incredibly important to know who's taking [PrEP], how often they are off and on it, and how well they adhere to the therapy. More and more people at risk are taking it at some point and are more likely to benefit from its protection against HIV.”